Hot Biotech Stocks For 2019

Drugs that help the immune system fight cancer are making a big difference for scores of patients, and stocks tied to companies developing them have done wonders for quite a few portfolios. The Loncar Cancer Immunotherapy Index, which tracks a revolving basket of drugmaker stocks that fit in this niche, is up 31.5% over the past year.

The general outlook for immuno-oncology is so bright that the niche index has thumped the broad market and the Nasdaq Biotechnology Index over the past year.

^LCI data by YCharts.

The strong patient responses we’ve seen from revolutionary new drugs combined with a frothy market for biotech buyouts have sent quite a few stocks skyward. Before you jump into the fray, though, you should understand a couple of challenges that many immuno-oncology stocks will face on the road ahead. 

A tough act to follow

From a commercial standpoint, the most successful class of drugs that help the immune system fight cancer are the PD-1 inhibitors. Opdivo, from Bristol-Myers Squibb (NYSE:BMY), and Keytruda, from Merck & Co. (NYSE:MRK), weren’t available a few years ago. But the pair will probably generate a combined $12 billion in sales this year.

Hot Biotech Stocks For 2019: Fonar Corporation(FONR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Fonar Co. (NASDAQ:FONR) Treasurer Raymond V. Damadian sold 1,320 shares of the firm’s stock in a transaction on Monday, June 25th. The shares were sold at an average price of $27.47, for a total value of $36,260.40. Following the completion of the transaction, the treasurer now owns 127,802 shares in the company, valued at approximately $3,510,720.94. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

  • [By Logan Wallace]

    Fonar Co. (NASDAQ:FONR) Treasurer Raymond V. Damadian sold 2,400 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $24.50, for a total value of $58,800.00. Following the sale, the treasurer now directly owns 123,202 shares in the company, valued at approximately $3,018,449. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

  • [By Shane Hupp]

    Fonar Co. (NASDAQ:FONR) Treasurer Raymond V. Damadian sold 900 shares of the stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $24.68, for a total value of $22,212.00. Following the completion of the sale, the treasurer now directly owns 121,852 shares of the company’s stock, valued at $3,007,307.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Hot Biotech Stocks For 2019: Genuine Parts Company(GPC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Gunpowder Capital Corp (CNSX:GPC) hit a new 52-week low on Wednesday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 3000 shares. The stock had previously closed at C$9.90.

  • [By ]

    Genuine Parts Company (NYSE: GPC), a distributor of automotive replacement parts in the United States and abroad, most recently raised its dividend payout by about 7 percent and it now yields 2.9 percent. GPC has paid a cash dividend every year since going public in 1948, and 2018 marks the 62nd consecutive year of dividend hikes.

  • [By Joseph Griffin]

    Shares of Genuine Parts (NYSE:GPC) have earned an average rating of “Hold” from the ten ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $99.40.

Hot Biotech Stocks For 2019: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of Cara Therapeutics (NASDAQ:CARA) rose over 17% last month, according to data provided by S&P Global Market Intelligence. The company announced that it had completed enrollment for its phase 3 clinical trial evaluating its lead drug candidate, Korsuva, as a potential treatment for chronic kidney disease-associated pruritus (CKD-aP) in patients on dialysis. That means top-line results from the study will be available sometime in the second quarter of 2019. 

  • [By Max Byerly]

    Cara Therapeutics Inc (NASDAQ:CARA) has earned an average recommendation of “Buy” from the seventeen analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $24.96.

  • [By Cory Renauer]

    Marijuana and opioids have been used to treat serious ailments for an awfully long time, and they’re about to get some important upgrades. Some investors are convinced GW Pharmaceuticals PLC (NASDAQ:GWPH) and Cara Therapeutics Inc. (NASDAQ:CARA) have found the right way to improve on some old favorites.

  • [By Brian Orelli]

    Shares of Cara Therapeutics (NASDAQ:CARA) jumped 26.3% in May, according to data provided by S&P Global Market Intelligence, after the biotech signed a partnership with Vifor Fresenius Medical Care Renal Pharma to license most of the ex-U.S. rights to Korsuva, Cara’s treatment for itching associated with chronic kidney disease in dialysis patients.

  • [By Ethan Ryder]

    Cara Therapeutics Inc (NASDAQ:CARA) SVP Frederique Ph.D. Menzaghi sold 3,000 shares of the stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $19.81, for a total transaction of $59,430.00. Following the transaction, the senior vice president now directly owns 98,000 shares in the company, valued at approximately $1,941,380. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

  • [By Keith Speights]

    One such biotech is GW Pharmaceuticals (NASDAQ:GWPH), which already has one cannabinoid product on the market in some countries and another one potentially on the way to approval in the U.S. Another biotech, Cara Therapeutics (NASDAQ:CARA), has a pre-clinical candidate cannabinoid-receptor agonist, CR701, which puts it ever-so-loosely in the marijuana stock category.

Leave a Reply

Your email address will not be published. Required fields are marked *